Alamar Biosciences ALMR
- Market cap
- $2B
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| $13.1M | $16.2M | $26M | $29.4M | |
| Cost of revenue | $6.7M | $7.6M | $11.6M | $11.7M |
| Gross profit | $6.4M | $8.6M | $14.5M | $17.7M |
| R&D | $8.3M | $8.9M | $13M | $13.8M |
| SG&A | $6.6M | $7.6M | $13.8M | $17.4M |
| −$8.6M | −$7.9M | −$12.3M | −$13.5M | |
| Interest expense | $46K | $48K | $223K | $224K |
| Pre-tax income | −$7.7M | −$7M | −$20.9M | −$13.3M |
| n/a | n/a | $464K | −$93K | |
| Net income | −$7.7M | −$7M | −$21.3M | −$13.2M |
| −$0.68 | −$0.62 | −$1.74 | −$0.22 | |
| 11.3M | 11.4M | 12.3M | 58.7M |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Alamar Biosciences' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| ALMRAlamar Biosciences | $2B | n/m | n/a | n/m | n/m | n/m | |
| VCYTVeracyte | $3.9B | 35.0× | 66.2× | 7.0× | +17% | 20.4% | |
| CDNACareDx | $4.5B | 35.9× | 19.2× | 9.1× | +39% | 25.9% | |
| BLLNBillionToOne | $5.2B | 170× | 152× | 13.1× | +90% | 9.5% | |
| LNTHLantheus | $6.5B | 24.3× | 24.0× | 4.2× | +2% | 17.7% | |
| NRCNRC Health | $536.6M | 97.0× | 35.2× | 3.8× | −0% | 4.2% | |
| CAICaris Life Sciences | $9.1B | 86.8× | 78.4× | 9.2× | +85% | 10.6% | |
| BIOBio-Rad Laboratories | $9.8B | 44.4× | 30.9× | 3.8× | +1% | 8.6% | |
| RVTYRevvity | $16.9B | 72.2× | 35.1× | 5.8× | +4% | 8.2% | |
| MEDPMedpace | $18.1B | 38.0× | 34.5× | 6.5× | +25% | 17.7% | |
| Peer median | $6.5B | 44.4× | 35.1× | 6.5× | +17% | 10.6% |
Investors who own it
Investors we follow who held Alamar Biosciences at the end of Jun 30, 2026, from their 13F filings.
- Cathie WoodARK Investment Management0.2% of portfolionew
More on Alamar Biosciences
Each number over time
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .